ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

14 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

    Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

  • Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
Bfl-1 [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50) >10 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  Mki0R4VtdCCYaXHibYxqfHliQYPzZZk> MUCyOVAhdk4EoB?= NILpfmo4OiCq NFLLdZJFVVOR NFLwXJlk[XW|ZXSgPVcmKGyxc4Ogc4YhfmmjYnnsbZR6KGmwIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghSkOONjDzbXJPSQ>? NFz4Z3EzPjZ3N{K4PC=>
KG1a NVfZNWhXS2WubDDWbYFjcWyrdImgRZN{[Xl? MUGwMVExKM7:TR?= NGXxWZAzPCCq NHi2XHVFVVOR MUnJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUe2[GE5OjZ3NUK3NVI>
Kasumi-1 MnTKR4VtdCCYaXHibYxqfHliQYPzZZk> NYjsOYxpOC1zMDFOwG0> MXSyOEBp NGfmcFJFVVOR NGXvTFRKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnf6NlY2PTJ5MUK=
KG1a M331SmFxd3C2b4Ppd{BCe3OjeR?= M3\SR|AuOTBizszN NITtbJIzPCCq M{fBPWROW09? MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3S4[|I3PTV{N{Gy
Kasumi-1 NYHXZY1qSXCxcITvd4l{KEG|c3H5 MV[wMVExKM7:TR?= NIHqflYzPCCq MkHiSG1UVw>? Ml61bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlzENlY2PTJ5MUK=
MC-3  MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG1M|ExNzJyIN88US=> MlvxNlQhcA>? NHfIXJVFVVOR M2HzXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoSyNlY1PDd4MUW=
HN22  M3XwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv5Z3o6Oi53L{euOU8zOi53IN88US=> MmfNNlQhcA>? M4DMTWROW09? MnHabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXztR2xwOjZ2NEe2NVU>
MC-3  NW\KN|VZSXCxcITvd4l{KEG|c3H5 NHjsTmM2NzFyL{KwJO69VQ>? Moe2NlQhcA>? M4LxNmROW09? M1\pV4lv\HWlZYOgZ4F{eGG|ZT3t[YRq[XSnZDDhdI9xfG:|aYO= NHXsc|UzPjR2N{[xOS=>
HN22  M3nvfGFxd3C2b4Ppd{BCe3OjeR?= NFjTPXozNjVxNz61M|IzNjVizszN NWHpdZZKOjRiaB?= NEW0SJJFVVOR NUm5bJBxcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> M2POcFI3PDR5NkG1
MOLT-4 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\wV5YyOC13MECwJI5O MW[3NkBp MUfEUXNQ MYXJR|UxRTBwMUm4JO69VQ>? NVPwSo9SOjZ|OUKzN|I>
RS4;11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmxNE02ODByIH7N MorhO|IhcA>? M1XpVGROW09? MWLJR|UxRTBwMECyJO69VQ>? NF[yNoMzPjN7MkOzNi=>
JURKAT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNE02ODByIH7N M1rxRVczKGh? MXLEUXNQ MlHiTWM2OD14NjFOwG0> NIPCXoIzPjN7MkOzNi=>
CEM R M2S0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHDNVAuPTByMDDuUS=> NXu0W3p[PzJiaB?= M3q0VGROW09? MkjETWM2OD13LkSg{txO Ml7FNlY{QTJ|M{K=
CEM S NVTFeY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULSUYdKOTBvNUCwNEBvVQ>? MmXYO|IhcA>? M4PTfmROW09? M33ScGlEPTB;MUKuNUDPxE1? MojrNlY{QTJ|M{K=
MOLT-4 MkXRRZBweHSxc3nzJGF{e2G7 NYflNWN4OTBvMUCwNEBvVQ>? NGjVeHIzPCCq MUDEUXNQ MVvjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= MV[yOlM6OjN|Mh?=
CEM S NV;lUGE6SXCxcITvd4l{KEG|c3H5 MnzLNVAuOTByMDDuUS=> NH35SnYzPCCq NFfrem9FVVOR M4LMc4NifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x MY[yOlM6OjN|Mh?=
JURKAT MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTZUZMyODBvMUCwNEBvVQ>? MkXoOFghcA>? MWnEUXNQ MWjJR|UxRTl3NdMxPU4{KG6P M1\mZ|I3OTd{Mk[5
LOUCY MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLvNVAxNTFyMECgcm0> NVL0TYZOPDhiaB?= M1noWmROW09? NGHUNIVKSzVyPUOyMljDuTFyLkmgcm0> MkG0NlYyPzJ{Nkm=
WM-115 MlnFR4VtdCCYaXHibYxqfHliQYPzZZk> MnHSNVAxyqCwTR?= MVm3NkBp MYLlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? NUL6UZpTOjZzMU[3O|Y>
B16 M4fwSWNmdGxiVnnhZoltcXS7IFHzd4F6 M{LGc|ExOMLibl2= NE\V[Ys4OiCq NFH6b2lmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MXiyOlEyPjd5Nh?=
HL-60  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe3NkBp M3XodWlEPTEEoE2gNVAvPyCwTR?= MVKyOlA1PTZyOR?=
MOLM-13  M1K4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnuT3Y4OiCq NUDOfGZnUUN3MNMgQUAzPy57IH7N NWi0bXA2OjZyNEW2NFk>
OCI-AML3 M1vFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YdVczKGh? NEO3elFKSzVywrC9JFE6PTBibl2= MoWwNlYxPDV4MEm=
BCWM.1 MX7BdI9xfG:|aYOgRZN{[Xl? MmfENE0yNjZizszN MVKyOEBp MVPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3rINVI2QDl|Mkmw
MWCL-1 MUfBdI9xfG:|aYOgRZN{[Xl? MViwMVEvPiEQvF2= NW\VU3NnOjRiaB?= M{PLSolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2LqNVI2QDl|Mkmw
MM.1s NWHNdHJOSXCxcITvd4l{KEG|c3H5 NHfHVIsxNTFwNjFOwG0> NWXy[4RDOjRiaB?= MnHBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGHZfnIzPTh7M{K5NC=>
HCT116 NVHiUHBwTnWwY4Tpc44hSXO|YYm= NILPSm4{NzFyIN88US=> M1XiZVEzyqCqwrC= NXfRfmxvTE2VTx?= MkLSbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NXnDSGdWOjV5MUWwNlg>
HCT116 BAX BAK1 DKO NE\yRXBHfW6ldHnvckBCe3OjeR?= MlLCN{8yOCEQvF2= M2DHO|EzyqCqwrC= NWTvO5p3TE2VTx?= NV3z[otncW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u NXPNXZp7OjV5MUWwNlg>
HCT116 MVfGeY5kfGmxbjDBd5NigQ>? NUSxVJV3OTBizszN NGiwengyOsLiaNMg MnvNSG1UVw>? MXzpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj M2i0ZVI2PzF3MEK4
HCT116 BAX BAK1 DKO M{DPbWZ2dmO2aX;uJGF{e2G7 MkS3NVAh|ryP NV3DW5NmOTMEoHlCpC=> Mn;FSG1UVw>? MVjpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj M2rVdlI2PzF3MEK4
HCT116 NYTSeJE6SXW2b4DoZYd6KEG|c3H5 MU[xNEDPxE1? NEjBdmEyOsLiaNMg M3HuZ2ROW09? NIWyVGhqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? MkLsNlU4OTVyMki=
HCT116 BAX BAK1 DKO M1T5dWF2fG:yaHHnfUBCe3OjeR?= M4SzUVExKM7:TR?= MVOxNuKhcMLi NHfrVmJFVVOR M1i3Uolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm M3G4V|I2PzF3MEK4
U937 NVzESVF6SXCxcITvd4l{KEG|c3H5 NULWVpFzOC5zMkWtNkDPxE1? NEPOdVYzPCCq MV;lcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= MomxNlU4OTRyMkS=
U937  NX;rTWxYSXCxcITvd4l{KEG|c3H5 NH6xdWgxNjVizszN MVWyOEBp NU\QenlI\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=> MVqyOVcyPDB{NB?=
HL-60 AAA-Bcl-2 NYO2dXJ[SXCxcITvd4l{KEG|c3H5 MXWwMVUh|ryP M4O4[FQ5KGh? NXrlOmV{UUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2\UWlI2PzFzNE[w
HL-60 EEE-Bcl-2 NG\PeVNCeG:ydH;zbZMhSXO|YYm= MWWwMVUh|ryP MoHEOFghcA>? NHe3NoxKSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHzW[YozPTdzMUS2NC=>
U87 M3fs[mZ2dmO2aX;uJGF{e2G7 MYm1NEDPxE1? MlfNNlQhcA>? MkmxdoVlfWOnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBOVVBvMjygUW1RNTF2IHHu[EBD[2xvMh?= M3j1VVI2PjZ5Nk[z
K562 M2fQXWNmdGxiVnnhZoltcXS7IFHzd4F6 NFjXUFgyNTFyIN88US=> NFLi[WI1QCCq MnPhSG1UVw>? M3XqOWlEPTB;Mk[uO{DPxE1? NGrTSYUzPTV7NkW2NS=>
K562/Mcl -1-IRESBim MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m4bmlEPTB;OT6zJO69VQ>? MmPKNlU2OzV7MEC=
K562/Bcl- 2-IRESBim NWf0R|lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvmd49KSzVyPUCuN|Uh|ryP M4nY[VI2PTN3OUCw
Jurkat NGnCNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNk[g{txO NUfDPHdxOjV3M{W5NFA>
JurkatΔBak NUnNOVhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17oUGlEPTB-NUCg{txO MXuyOVU{PTlyMB?=
HL60/VCR NHzZb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe1UZZKSzVyPkGwNEDPxE1? NEnYcZUzPTV|NUmwNC=>
Kasumi-1 NEnvfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnOe3FKSzVyPUCuNFEh|ryP MWSyOVU{PTlyMB?=
Kasumi-1/ABT NWX3blhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXlTWM2OD1yLkWxJO69VQ>? MmjLNlU2OzV7MEC=
THP-1 NEHlV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjnbXpKSzVyPUGuNlch|ryP NHfHNmUzPTV|NUmwNC=>
U937 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;X[2lEPTB;NT6yPUDPxE1? M1rIfVI2PTN3OUCw
C1498 NX[3N4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO0TWM2OD14LkGzJO69VQ>? M2TPUFI2PTN3OUCw
RPMI 8226 NXjJRW9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlcWlEPTB;MD6yOUDPxE1? MXWyOVU{PTlyMB?=
MM.1S NW\YW4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwNECg{txO M1rxSFI2PTN3OUCw
NCI-H929 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnHTWM2OD1zNT6yNUDPxE1? MmrXNlU2OzV7MEC=
U266 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjrTGlKSzVyPUCuOlgh|ryP NXjkWnRROjV3M{W5NFA>
MCF-7 NEXqTIxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXjES2VDPSEQvF2= MlftOFghcA>? MmPnSG1UVw>? Mlu5[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? NF[3WmMzPTRyOUGyOC=>
MCF-7 M4HlRWFxd3C2b4Ppd{BCe3OjeR?= M{freVUh|ryP NYXrbVdEPC9{ND:0PEBp MYLEUXNQ NFK5VJBqdmO{ZXHz[ZMhfGinIHPs[YF3\WRiUFHSVC=> MWqyOVQxQTF{NB?=
MCF-7 MYjGeY5kfGmxbjDBd5NigQ>? MkT3OUDPxE1? MXSyOEBp MlXYSG1UVw>? MYjlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> NX3S[oE4OjV2MEmxNlQ>
MDA-MB 231  NIfq[GtHfW6ldHnvckBCe3OjeR?= NHPsTYM2KM7:TR?= M4L2WVI1KGh? M{jZSGROW09? NUjRWZg{\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MnLGNlU1ODlzMkS=
ZR-75-1  NGXLS3ZHfW6ldHnvckBCe3OjeR?= NHTRXXU2KM7:TR?= M{izUVI1KGh? NWTRPHlSTE2VTx?= MYrlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> NEDv[owzPTRyOUGyOC=>
A549 MnTRR4VtdCCYaXHibYxqfHliQYPzZZk> MnHBNE0zOCEQvF2= M3nwdVczKGh? NGiyVWJFVVOR MXrk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MnPnNlU{QDh5NkK=
H1299 NVzneJhRS2WubDDWbYFjcWyrdImgRZN{[Xl? MWGwMVIxKM7:TR?= MmTkO|IhcA>? NHP5bVdFVVOR NWrGWm1E\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M4LKWFI2Ozh6N{[y
HO-8910 M4TSZmNmdGxiVnnhZoltcXS7IFHzd4F6 NYnweVczOC1{MDFOwG0> NVjuemRHPzJiaB?= MWfEUXNQ Ml73[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NWWzbXFDOjV|OEi3OlI>
HT-29 M{fP[WNmdGxiVnnhZoltcXS7IFHzd4F6 NVXV[|V4OC1{MDFOwG0> M4HId|czKGh? NFL3SlhFVVOR NXraeYZN\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M1LwcVI2Ozh6N{[y
HCT-116 NYq3eYl{S2WubDDWbYFjcWyrdImgRZN{[Xl? MWiwMVIxKM7:TR?= NVG4fFdjPzJiaB?= NYXrXnlPTE2VTx?= NXr0N3d{\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NVvETm4yOjV|OEi3OlI>
A549 MorPRZBweHSxc3nzJGF{e2G7 MorqNlAh|ryP MlPHOFghcA>? MWXEUXNQ NYfDN2U3cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> NUjBZo1[OjV|OEi3OlI>
H1299 M1HFS2Fxd3C2b4Ppd{BCe3OjeR?= MVKyNEDPxE1? NGS4U2E1QCCq MWHEUXNQ MUnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NHLobJAzPTN6OEe2Ni=>
Sc-1 NF24UVVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3\LVlAvODByMT2xJO69VQ>? MY[5OkBp MoXr[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkGzNlU{PzN3MEi=
OcI-LY18 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYHQWm1bOC5yMECxMVEh|ryP NW\a[YFDQTZiaB?= MXzk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWLufmxDOjV|N{O1NFg>
RL  M3K3V2NmdGxiVnnhZoltcXS7IFHzd4F6 NI\wSmcxNjByMEGtNUDPxE1? NEjwOIM6PiCq NVzUc2xU\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYnOSYZTOjV|N{O1NFg>
RKO MnLaR4VtdCCYaXHibYxqfHliQYPzZZk> NGrISmoxNTFyIN88US=> MXyyOQKBkWkEoB?= M1HlNmROW09? M1L1[mlEPTB-4pEJNlXjiIoEtV2= NFTIOZozPTNyNEO4Ny=>
Caco-2 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVKwMVExKM7:TR?= MXqyOQKBkWkEoB?= MYnEUXNQ MlnuTWM2OD1zOT635qCKyrWP MVeyOVMxPDN6Mx?=
DLD1 NWfHXZQxS2WubDDWbYFjcWyrdImgRZN{[Xl? MlfHNE0yOCEQvF2= NVrhN4ZZOjUkgJnoxsA> MY\EUXNQ MWHJR|UxRTF6Lke45qCKyrWP NWfS[o5JOjV|MESzPFM>
LS411N MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVrYUIp[OC1zMDFOwG0> MlX0NlTjiImqwrC= NEDBfG1FVVOR NH\LRZVKSzVyPUGxMlQ46oDLwsXN MWiyOVMxPDN6Mx?=
SW620 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1PvcFAuOTBizszN NHzzfIczPOLCiXlCpC=> MmTVSG1UVw>? NHXuWZVKSzVyPUGyMlI16oDLwsXN NFrOPVEzPTNyNEO4Ny=>
HCT116 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGrPVWgxNTFyIN88US=> NFn4[ZczPOLCiXlCpC=> M3nuS2ROW09? MoHzTWM2OD1{MD60PgKBkcL3TR?= NV;YbWlIOjV|MESzPFM>
HaCaT NEPRdY1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFTNZ|IxNjFxMT:xNEDPxE1? M1XOVFI1KGh? NFHjWFlFVVOR M4LMU4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{Xjc|I2OjFyN{m1
A5-RT3 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXv3O|FXOC5zL{GvNVAh|ryP NIf0NnUzPCCq NE\RUGxFVVOR MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1fud|I2OjFyN{m1
HaCaT MUXGeY5kfGmxbjDBd5NigQ>? M3rnWlEx6oDLzszN MUGyOE81QCCq M2HVUmROW09? NG[yTnNqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= NH\VcGEzPTJzMEe5OS=>
A5-RT3 NFnFfVVHfW6ldHnvckBCe3OjeR?= M4Dpb|Ex6oDLzszN M{L2bFI1NzR6IHi= MY\EUXNQ NIniPG5qdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= MUiyOVIyODd7NR?=
A5-RT3 M17EUWZ2dmO2aX;uJGF{e2G7 NXzOfGxIPSEQvF2= MXe2JIg> MnrMSG1UVw>? M{LxT4lv\HWlZYOgeIhmKHKnbHXhd4Uhd2ZibXn0c4Npd26mcnnhcEBxem:2ZXnud{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIP1dpZqfmGuIHnuJIEh[2G|cHHz[U1qdmSncHXu[IVvfCCvYX7u[ZI> NH3TUmgzPTJzMEe5OS=>
U266 NF7GcmxHfW6ldHnvckBCe3OjeR?= MUO1NFAwPzVyIH7N NGjseIozPC92ODDo NXfqSZhZTE2VTx?= MV7kc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M4rQdFI2OjB6OEi4
RPMI8226 MlzwSpVv[3Srb36gRZN{[Xl? MUm1NFAwPzVyIH7N NET6VXgzPC92ODDo NWf1RlkxTE2VTx?= M3vHOoRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> NGK4b4kzPTJyOEi4PC=>
MM.1S MX\GeY5kfGmxbjDBd5NigQ>? M3\BZ|UxOC95NUCgcm0> MUeyOE81QCCq NV7ZO|VRTE2VTx?= NGrEd5Vld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NUjDXGdKOjV{MEi4PFg>
Clone A MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjQXnhFOC5{4pETOlAh|ryP M1;1e|czKGh? MU\EUXNQ MnrITWM2OD15LkWg{txO NVqz[3RiOjV{MEi4PFI>
CX-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3zdZUxNjMkgKO2NEDPxE1? NHzWbpI4OiCq MXXEUXNQ MXXJR|UxRTFwODFOwG0> MWOyOVIxQDh6Mh?=
LS174T NYjhbZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPUS3NCOC5{4pETOlAh|ryP NF7ZSlE4OiCq MV;EUXNQ MkT2TWM2OD1zOD6zJO69VQ>? MlfFNlUzODh6OEK=
HT29 NYPRblE4SXCxcITvd4l{KEG|c3H5 NYTy[GlHOS93L{GwJO69VQ>? MX:0PEBp NYrqXHA2[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NX3BT4F4OjVzOUKxPFg>
SW480 NGnVSGFCeG:ydH;zbZMhSXO|YYm= Mli0NU82NzFyIN88US=> NIri[Fk1QCCq NEXKd5Jk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoHnNlUyQTJzOEi=
Colo205 NXLmSolvSXCxcITvd4l{KEG|c3H5 NEfVWZoyNzVxMUCg{txO MXK0PEBp NYrnUI5T[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGHVNGgzPTF7MkG4PC=>
Caco2 MnvrRZBweHSxc3nzJGF{e2G7 M{nhSFEwPS9zMDFOwG0> MWC0PEBp NETUbHNk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH\ac5czPTF7MkG4PC=>
PCI-13 M2HWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jsSFczKGh? M3uwXWROW09? NFvX[oJIUTVyPUG1JOKyKDFwODFOwG0> MnnjNlUyOzl|OEe=
PCI-15B MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrYSIU4OiCq NVvwOZJ2TE2VTx?= MmKwS2k2OD1zMTFCtUA1NjVizszN M2j1PVI2OTN7M{i3
UM-SCC22B MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfLcXU4OiCq M2nCcGROW09? MXTHTVUxRTF7INMxJFIvQSEQvF2= M{DYWFI2OTN7M{i3
UM-SCC47 NGLnWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCxeIt3PzJiaB?= MYPEUXNQ MojzS2k2OD1zOTFCtUAyOi5|IN88US=> Mm\INlUyOzl|OEe=
93-VU-147T M17r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZdlczKGh? M4\ZeGROW09? Ml7ES2k2OD12LkOgxtEhOy53IN88US=> MnzMNlUyOzl|OEe=
UD-SCC2 NInDTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPDV5hwPzJiaB?= MYjEUXNQ NXvLbpU1T0l3ME2yPEDDuSB{Lkmg{txO MmrFNlUyOzl|OEe=
UPCI:SCC90 M1PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3emQzPzJiaB?= NGTxbFFFVVOR MXrHTVUxRTZwNjFCtUAyNjVizszN NITW[5ozPTF|OUO4Oy=>
RPMI-8226  NHHH[m9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1njOlEzPS9{NUCvOVAxKG6P MlXUOFhpyqB? MYXEUXNQ MmH5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXuwSYFHOjVyMEiyNFI>
OPM-2  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUPsb5g5OTJ3L{K1NE82ODBibl2= NXPmV|JyPDiqwrC= MX3EUXNQ M{PkRoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlPkNlUxODh{MEK=
RPMI-8226  NVHRUnpwSXCxcITvd4l{KEG|c3H5 NFrobFgyOjVxMkWwM|UxOCCwTR?= M4\qclQ5cMLi MVfEUXNQ NXTY[JVmcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnPCNlUxODh{MEK=
OPM-2  MVHBdI9xfG:|aYOgRZN{[Xl? M1r5d|EzPS9{NUCvOVAxKG6P MXe0PIjDqA>? M1\nVWROW09? NHnSR5ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUnwS2xFOjVyMEiyNFI>
COG-LL-319 NXXzXXpsTnWwY4Tpc44hSXO|YYm= MXexNFAhdk1? MUGxM|MwPiCq M2LvSGROW09? MlTlbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MUeyOFk2OTR5Mh?=
RS4;11 NF;GXYJHfW6ldHnvckBCe3OjeR?= M2HPRlExOCCwTR?= NX;XRZJVOS9|L{[gbC=> NWqwb5RXTE2VTx?= MonHbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MlHRNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% Propylene glycol, 5% Tween 80, 65% D5W 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID